CD274 and hepatocellular carcinoma: A phase 1b trial demonstrated that in patients with unresectable hepatocellular carcinoma, treatment with atezolizumab, an anti-PD-L1 antibody, combined with bevacizumab, a vascular endothelial growth factor A (VEGF-A) inhibitor, resulted in better overall and progression-free survival compared to sorafenib administration [17].